CD7 car-t, stem cell transplant, and kidney transplant for SIOD
Treatments studied
Part of Blood & lymphatic, Bones, joints & muscles, Genetic & congenital, Kidney & urinary clinical trials.
This trial tests a sequence of treatments for SIOD (a genetic condition causing immune and kidney problems). First, you receive CD7 car-t cells, then a stem cell transplant from a family donor, followed by a kidney transplant from the same donor. The goal is to see if this approach is safe and can help your body accept the new kidney.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with SIOD and are in stage 5 chronic kidney disease (your kidneys function at less than 15% normal)
- You have a related donor who can provide both stem cells and a kidney (a haploidentical match is okay)
- Your liver function tests (bilirubin, ALT, AST) must be within set limits
- Your heart pumps normally (LVEF of 50% or higher on an echo) and you do not have severe heart disease or a prolonged QT interval
- You do not have an active lung infection and your oxygen level while breathing air is above 92%
- You have not had a stem cell or organ transplant before, and do not have HIV, active hepatitis B or C, or an active infection that is not cured
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immune cell therapy (CD7 CAR-T) given as a bridge to a stem cell transplant in people with relapsed or hard-to-treat CD7-positive leukemia. The goal is to help control the leukemia and improve chances for a successful transplant.
This trial tests a new approach for people with non-cancerous blood and immune system diseases. It uses your own engineered immune cells (CAR-T cells) to prepare your body for a stem cell transplant from a relative.
This trial tests a new CAR-T cell treatment for children and adults with steroid-resistant nephrotic syndrome (SRNS), a kidney condition that doesn't get better with standard medicines. The goal is to see if this therapy can help improve kidney function when other treatments have failed.
This early-phase trial tests a stem cell transplant from a donor who is an extremely close match, given to people who are about to receive a kidney transplant from the same donor. The goal is to improve how well the new kidney works by resetting the immune system to better accept the transplant.
This trial is testing a new, gentler type of bone marrow transplant for children and young adults with sickle cell disease who have a healthy sibling donor with a mismatched blood type or who have antibodies against their donor's red blood cells. The goal is to replace the faulty bone marrow with healthy donor cells, with fewer side effects than traditional transplants.
This Phase 2 trial looks at a transplant approach that reduces harmful immune cells (T cells) before or during an allogeneic stem cell transplant. It may help lower the risk of transplant complications while still letting the donor immune system fight the blood cancer.
Hear when a new Schimke Immuno-osseous Dysplasia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.